Regeneron Just Cured a Type of Deafness With a Single Surgery

It's worth noting this is an accelerated approval, meaning Regeneron still needs to prove the hearing gains last and translate into real-world improvements in speech development and quality of life. But the early results were compelling enough for the FDA to say "go."

Why This Matters Beyond the Ear

Let's zoom out. Regeneron is a company built on antibodies. Dupixent (its blockbuster allergy and asthma drug, co-marketed with Sanofi) and Eylea (its retinal disease franchise) are the twin engines that made it a $100 billion-plus powerhouse. Everything about the company's identity, from its VelociSuite platform to its massive Regeneron Genetics Center (which has sequenced over 2 million exomes), has been optimized for discovering protein-based medicines.

Getting into gene therapy is like a Michelin-starred Italian chef deciding to open a sushi restaurant. The foundational skills overlap, sure, but the execution is completely different. AAV vectors, surgical delivery, one-time dosing models: these are new muscles for Regeneron.

And the timing is telling. The gene therapy field has been through a rough stretch lately. Pfizer pulled its FDA-approved hemophilia B gene therapy Beqvez off the market in February 2025 after literally zero commercial uptake. Vertex abandoned AAV technology entirely. Several other large-cap players, including Roche, Takeda, and Biogen, have scaled back their gene therapy ambitions due to safety concerns, manufacturing headaches, and pricing challenges.

With one-time AAV treatments priced anywhere from $850,000 to $4.5 million per dose, the commercial math is brutal. You need to identify every eligible patient, convince insurers to cover a seven-figure treatment, and do it all before your competitors catch up.

The Small Market With a Big Signal

OTOF-related deafness accounts for just 2-8% of inherited, non-syndromic congenital hearing loss. That translates to roughly 50 affected newborns per year in the U.S. This is not going to be a billion-dollar drug by volume.

But that's probably not the point. For Regeneron, Otarmeni is a proof of concept: evidence that its genetics-first approach to drug discovery can extend beyond antibodies into entirely new therapeutic modalities. The company's Genetics Center identifies targets. Its platforms build the therapies. And now it has shown it can take a gene therapy from lab bench to FDA approval.

Regeneron has also been expanding aggressively in other directions. It recently struck a 50/50 partnership with Telix Pharmaceuticals to develop radiopharmaceutical cancer therapies (a deal worth up to $2.1 billion in milestones). In 2024, it acquired 2seventy bio's investigational cell therapies to form Regeneron Cell Medicines. The company is clearly building a toolkit that goes far beyond traditional biologics.

What Comes Next

The gene therapy landscape is at a crossroads. Thousands of gene and cell therapies are currently in development. But the field's track record of converting approvals into commercial success has been, to put it gently, inconsistent.

Regeneron's advantage is that it doesn't need Otarmeni to pay the bills. Dupixent and Eylea do that. What it needs is validation that its platform can deliver across modalities, and that's exactly what this approval provides.

For the 50 or so families each year who learn their child carries biallelic OTOF mutations, the stakes are more personal. Before last Friday, the best they could hope for was a cochlear implant and years of speech therapy. Now there's a single surgery that could let their child hear naturally.

The side effects are relatively mild (middle ear infections, nausea, dizziness, and procedural pain), and the biggest remaining question is durability. Will the hearing gains hold up over years, or even decades? That's what the post-approval studies will need to answer.

But for a condition that had zero disease-modifying treatments before last week, "we need to see if it lasts" is a pretty good problem to have.